Argonautica Private Wealth Management Inc. Trims Stock Holdings in Eli Lilly and Company $LLY

Argonautica Private Wealth Management Inc. trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 3.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,095 shares of the company’s stock after selling 113 shares during the quarter. Argonautica Private Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $2,413,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of LLY. PNC Financial Services Group Inc. raised its holdings in shares of Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after buying an additional 50,002,551 shares during the period. Nuveen LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter worth approximately $4,613,912,000. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after buying an additional 4,975,395 shares during the period. Cohen Investment Advisors LLC raised its holdings in shares of Eli Lilly and Company by 7,975.5% in the first quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company’s stock worth $647,225,000 after buying an additional 773,947 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Eli Lilly and Company by 106.8% in the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after buying an additional 765,010 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO David A. Ricks purchased 1,632 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jamere Jackson purchased 200 shares of the business’s stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders bought 4,514 shares of company stock worth $2,894,841. Insiders own 0.14% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on LLY shares. BMO Capital Markets increased their price target on Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a report on Monday. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Guggenheim restated a “buy” rating and set a $948.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 16th. The Goldman Sachs Group raised their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Finally, Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $938.61.

Eli Lilly and Company Trading Down 1.1%

Shares of NYSE:LLY opened at $799.85 on Wednesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $935.63. The business’s fifty day simple moving average is $759.77 and its 200-day simple moving average is $766.43. The company has a market capitalization of $757.03 billion, a PE ratio of 52.28, a P/E/G ratio of 1.16 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the business posted $3.92 EPS. The business’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.